Sequence 1 (CSK , EPHB2 , FGFR3 , FGFR4 , TNK2 , RIPK4 ( Homo sapiens ))

Sequence CSK , EPHB2 , FGFR3 , FGFR4 , TNK2 , RIPK4 ( Homo sapiens )
Target	CSK , EPHB2 , FGFR3 , FGFR4 , TNK2 , RIPK4 ( Homo sapiens )
Description	ENSG00000103653 15:74782057-74803198:1 C-src tyrosine kinase ; ENSG00000133216 1:22710839-22921500:1 EPH receptor B2 ; ENSG00000068078 4:1793307-1808872:1 Fibroblast growth factor receptor 3 ; ENSG00000160867 5:177086886-177098144:1 Fibroblast growth factor receptor 4 ; ENSG00000061938 3:195863364-195911945:-1 Tyrosine kinase, non-receptor, 2 ; ENSG00000183421 21:41739369-41767106:-1 Receptor-interacting serine-threonine kinase 4
Design	gapmer
Chemistry	+T*+T*+G*C*G*G*G*C*A*G*C*C*+A*+G*+G
Sequence	TTGCGGGCAGCCAGG
Application	Gene silencing , multitargeting
Name	CSK , EPHB2 , FGFR3 , FGFR4 , TNK2 , RIPK4 ( Homo sapiens )

References

Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypes. Varela MA. BMC Genomics. 2015 Jul 18;16(1):530.

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience. Hache M, Swoboda KJ, Sethna N, Farrow-Gillespie A, Khandji A, Xia S, Bishop KM. J Child Neurol. 2016 Jun;31(7):899-906. PubMed:26823478

Comments

Not experimentally validated

Background